Barclays Lowers Axon Enterprise (NASDAQ:AXON) Price Target to $682.00

Axon Enterprise (NASDAQ:AXON) had its price target cut by investment analysts at Barclays from $702.00 to $682.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 23.96% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC lowered their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Wall Street Zen cut Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. The Goldman Sachs Group cut their price target on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Piper Sandler reduced their price objective on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Royal Bank Of Canada dropped their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus target price of $762.93.

Axon Enterprise Trading Up 5.8%

NASDAQ AXON opened at $550.19 on Wednesday. The firm has a market capitalization of $43.42 billion, a PE ratio of 361.97, a price-to-earnings-growth ratio of 15.67 and a beta of 1.48. The business’s 50-day moving average price is $538.95 and its two-hundred day moving average price is $627.46. The company has a current ratio of 2.53, a quick ratio of 2.89 and a debt-to-equity ratio of 0.53. Axon Enterprise has a 12 month low of $396.41 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The company had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm’s revenue was up 38.5% compared to the same quarter last year. During the same period last year, the company earned $2.08 earnings per share. On average, analysts expect that Axon Enterprise will post 5.8 EPS for the current year.

Insider Buying and Selling

In other news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $551.92, for a total value of $5,519,200.00. Following the completion of the sale, the chief executive officer owned 3,110,997 shares in the company, valued at $1,717,021,464.24. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Joshua Isner sold 20,000 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the transaction, the president owned 249,502 shares in the company, valued at approximately $137,874,805.20. This trade represents a 7.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 58,040 shares of company stock valued at $32,251,738. 4.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Axon Enterprise by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after acquiring an additional 53,060 shares during the period. Geode Capital Management LLC increased its holdings in Axon Enterprise by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after buying an additional 35,544 shares during the last quarter. Baillie Gifford & Co. raised its position in Axon Enterprise by 1,198.7% in the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after acquiring an additional 1,516,099 shares during the period. Sands Capital Management LLC lifted its stake in Axon Enterprise by 11.6% in the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after purchasing an additional 167,095 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in Axon Enterprise by 326.9% during the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after purchasing an additional 1,179,038 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 results materially beat expectations — revenue +39% to ~$796.7M and non‑GAAP EPS $2.15 vs. consensus — and management reiterated aggressive growth targets and large contracted bookings, which drove investor optimism. Axon’s Q4 Earnings Top Estimates
• Positive Sentiment: Company highlighted AI adoption across its device + software platform (body cams, TASER 10, evidence management) and reported strong net revenue retention and bookings/backlog growth — messaging that the hardware‑to‑software flywheel reduces AI disruption risk and supports revenue expansion. Taser Maker Axon Says Its Business Is Being ‘Supercharged by AI.’
• Positive Sentiment: Market reaction: multiple outlets and analysts upgraded tone or reiterated buy cases based on the beat and 2026+ targets, lifting momentum after a prior steep selloff tied to SaaS/AI fears. Taser-maker Axon pops 18% as AI boosts demand
• Neutral Sentiment: Analyst price‑target revisions are mixed: several firms trimmed targets post‑report (Barclays, Morgan Stanley, Piper Sandler) but many maintain overweight/buy views — the market is re‑pricing near‑term risk while keeping upside scenarios. These Analysts Cut Their Forecasts On Axon
• Neutral Sentiment: Short-interest data in the feed appears anomalous (reporting 0 shares / NaN changes) and shows no meaningful days‑to‑cover signal — treat that data as unreliable for trading decisions today.
• Negative Sentiment: An insider transaction: CEO Patrick W. Smith sold 10,000 shares at ~$500.24 (filed with the SEC). The sale is small relative to total holdings but may be viewed negatively by some traders. SEC Form 4
• Negative Sentiment: Profitability caveat: several pieces note that while top‑line growth is accelerating, margins/profitability have not fully caught up — a risk if investors rotate to profitability metrics. Axon Stock Is On Fire, But Here’s the Bad News

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.